title: [Early treatment of acute hepatitis C with interferon alpha-2b or interferon alpha-2b plus ribavirin: study of sixteen patients].
abstract: OBJECTIVE
  To assess the mode of transmission and the efficacy of antiviral therapy in the outcome of treated and untreated patients with acute hepatitis C.
  
  
  METHODS
  From December 1995 to January 2001, 16 consecutive patients and their response to therapy were studied, including clinical, biochemical, virological and histological data.
  
  
  RESULTS
  Hepatitis C virus (HCV) exposure was IVDU (38%), needle-stick injury (19%), medical procedure (6%), piercing (6%), suspected sexual contact (19%), and unknown in 2. Among 13 patients treated for acute hepatitis C, all 12 patients who completed therapy had a biochemical and virological sustained response for more than 15 months (range: 4-36 months) after stopping therapy. Therapy was tolerated in all but one patient, who stopped after 10 weeks because of side effects. Duration of treatment, type of interferon and combination with ribavirin did not modify the response to treatment.
  
  
  CONCLUSIONS
  These results suggest that early intervention with interferon alpha is effective in preventing the progression of acute HCV infection to chronic hepatitis in most patients regardless of duration, type of interferon, or combination with ribavirin.
authors.affiliation: Service d'Hépatologie et de Gastroentérologie, Hôtel-Dieu, Lyon.
authors.forename: Pierre
authors.initials: P
authors.lastname: Rocca
authors.forename: François
authors.initials: F
authors.lastname: Bailly
authors.forename: Michèle
authors.initials: M
authors.lastname: Chevallier
authors.forename: Philippe
authors.initials: P
authors.lastname: Chevallier
authors.forename: Fabien
authors.initials: F
authors.lastname: Zoulim
authors.forename: Christian
authors.initials: C
authors.lastname: Trépo
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D001247:Asthenia / Q000821:virology; D003967:Diarrhea / Q000821:virology; D004359:Drug Therapy, Combination; D005260:Female; D006526:Hepatitis C / Q000188:drug therapy* / Q000209:etiology / Q000635:transmission; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007565:Jaundice / Q000821:virology; D008297:Male; D008875:Middle Aged; D016602:Needlestick Injuries / Q000150:complications; D010146:Pain / Q000821:virology; D011677:Punctures / Q000009:adverse effects; D011994:Recombinant Proteins; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use*; D012703:Serotyping; D012725:Sexual Behavior; D015819:Substance Abuse, Intravenous / Q000150:complications; D013653:Tattooing / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin
vernacular_title: Etude de seize cas d'hépatite C aiguë. Essai de traitement précoce par l'interféron alpha- 2b ou interféron alpha- 2b et ribavirine.